Clostridium Difficile Infection Treatment Market To Witness Tectonic GrowthPosted by Merin John on June 16th, 2021 The critical need for non-antibiotic alternatives for prophylaxis and treatment of Clostridium difficile infections is shaping the market landscape of Clostridium difficile infection treatment. The global Clostridium difficile infection treatment market was valued US$ 840 Mn in 2018 and will exhibit a promising CAGR during the forecast period (2019 – 2029). Key factors such as easy accessibility of diagnostic tests and accessibility of generic antimicrobial drugs (metronidazole and Vancomycin) continue to fuel the Clostridium difficile infection treatment market growth. Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15775 Company Profiles
Increasing incidence of Clostridium difficile infection demands for strengthening R&D program, thereby propelling growth of the Clostridium difficile infection treatment market. In 2017, Actelion conducted phase III clinical trial for comparing cadazolid with vancomycin for the treatment of Clostridium difficile associated diarrhea. As per Center for Disease Control & Prevention (CDC) 2015, prevalence of C. difficile infection is increasing and is most common healthcare-associated infection among adults. Key Takeaways – Clostridium difficile Infection Treatment Market Study
Launch of monoclonal antibody drugs for treatment of Clostridium difficile infection and counteractive action for recurrent Clostridium difficile infection has shifted the focus from antibiotics to recently approved therapeutic class of drugs. This new class of drugs represents a breakthrough and will create an extreme challenge for conventional antibiotic medicines for Clostridium difficile infection. Strategic Partnerships – Winning Imperatives for Market Leaders The key players are focusing on new product launches, collaborations, territorial expansion, mergers, and acquisitions to increase share in the market. Mergers and acquisitions are helping these players to enhance existing product portfolio and topographical reach. For example, to fortify their pharmaceutical business, Johnson & Johnson acquired Actelion Ltd, enhancing the product portfolio for Clostridium difficile infection treatment. To increase the market revenue, Astellas Pharma Inc. launched Dafclir Tablets 200 mg for the treatment of infectious enteritis (susceptible strains: fidaxomicin susceptible Clostridium difficile (CD)2) in Japan. To strengthen its product portfolio, USFDA granted acceptance for review of New Drug Application for DIFICID (fidaxomicin) for oral suspension in pediatric patients. More Valuable Insights on Clostridium difficile Infection Treatment Market Persistence Market Research offers a unique perspective and actionable insights on Clostridium difficile Infection treatment in its latest study, presenting historical demand assessment from 2014 – 2018 and projections from 2019 – 2029. The global Clostridium difficile infection treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Clostridium difficile infection treatment market on basis of drug type (Metronidazole, Vancomycin, Fidaxomicin), route of administration (oral, injectable) and distribution channel (hospital pharmacies, retail pharmacies, mail order pharmacies) across five major regions. Like it? Share it!More by this author |